Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada

Trial Profile

Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Pirfenidone (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 14 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 03 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 21 Mar 2017 Planned End Date changed from 1 Jun 2019 to 28 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top